Cargando…

Prevalence and Subtype Distribution of High-Risk Human Papillomavirus Among Women Presenting for Cervical Cancer Screening at Karanda Mission Hospital

PURPOSE: High-risk human papillomaviruses (hrHPV) are the primary cause of cervical cancer. Human papillomavirus (HPV) vaccination is expected to prevent cervical cancers caused by the HPV types included in vaccines and possibly by cross-protection from other types. This study sought to determine th...

Descripción completa

Detalles Bibliográficos
Autores principales: Thistle, Paul, Parpia, Rabea, Pain, Debanjan, Lee, Hang, Manasa, Justen, Schnipper, Lowell E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Clinical Oncology 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7456322/
https://www.ncbi.nlm.nih.gov/pubmed/32783640
http://dx.doi.org/10.1200/GO.20.00286
_version_ 1783575778269593600
author Thistle, Paul
Parpia, Rabea
Pain, Debanjan
Lee, Hang
Manasa, Justen
Schnipper, Lowell E.
author_facet Thistle, Paul
Parpia, Rabea
Pain, Debanjan
Lee, Hang
Manasa, Justen
Schnipper, Lowell E.
author_sort Thistle, Paul
collection PubMed
description PURPOSE: High-risk human papillomaviruses (hrHPV) are the primary cause of cervical cancer. Human papillomavirus (HPV) vaccination is expected to prevent cervical cancers caused by the HPV types included in vaccines and possibly by cross-protection from other types. This study sought to determine the hrHPV type distribution in women at a rural Zimbabwe hospital. METHODS: We implemented a cross-sectional study at the Karanda Mission Hospital. Using the Visual Inspection with Acetic Acid Cervicography technique, clinicians collected cervical swabs from 400 women presenting for screening for cervical cancer. Samples were initially analyzed by Cepheid GeneXpert; candidate hrHPV genotypes were further characterized using the Anyplex II HPV28 Detection Kit. RESULTS: Twenty-one percent of the 400 women were positive for a high-risk genotype when using the GeneXpert analyzer; 17% were positive when using the multiplex analysis. Almost two thirds of the hrHPV women had a single DNA type identified, whereas one third had multiple genotypes, ranging from 2 to 5. hrHPV was observed more frequently in HIV-positive than in HIV-negative women (27% v 15%). Of the 113 isolates obtained, 77% were hrHPV genotypes not included in the bivalent or quadrivalent vaccines, and 47% represented DNA types not covered in the nonavalent vaccine. Forty-seven percent of the women with hrHPV harbored a single genotype that was not covered by the nonavalent vaccine. CONCLUSION: A large fraction of hrHPV isolates from women participating in a cervical cancer screening program in northern Zimbabwe are DNA types not covered by the bivalent, quadrivalent, or nonavalent vaccines. These findings suggest the importance of characterizing the hrHPV DNA types isolated from cervical neoplasia in this population and determining whether cross-immunization against these genotypes develops after administration of the vaccines in current use.
format Online
Article
Text
id pubmed-7456322
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher American Society of Clinical Oncology
record_format MEDLINE/PubMed
spelling pubmed-74563222020-10-05 Prevalence and Subtype Distribution of High-Risk Human Papillomavirus Among Women Presenting for Cervical Cancer Screening at Karanda Mission Hospital Thistle, Paul Parpia, Rabea Pain, Debanjan Lee, Hang Manasa, Justen Schnipper, Lowell E. JCO Glob Oncol Original Reports PURPOSE: High-risk human papillomaviruses (hrHPV) are the primary cause of cervical cancer. Human papillomavirus (HPV) vaccination is expected to prevent cervical cancers caused by the HPV types included in vaccines and possibly by cross-protection from other types. This study sought to determine the hrHPV type distribution in women at a rural Zimbabwe hospital. METHODS: We implemented a cross-sectional study at the Karanda Mission Hospital. Using the Visual Inspection with Acetic Acid Cervicography technique, clinicians collected cervical swabs from 400 women presenting for screening for cervical cancer. Samples were initially analyzed by Cepheid GeneXpert; candidate hrHPV genotypes were further characterized using the Anyplex II HPV28 Detection Kit. RESULTS: Twenty-one percent of the 400 women were positive for a high-risk genotype when using the GeneXpert analyzer; 17% were positive when using the multiplex analysis. Almost two thirds of the hrHPV women had a single DNA type identified, whereas one third had multiple genotypes, ranging from 2 to 5. hrHPV was observed more frequently in HIV-positive than in HIV-negative women (27% v 15%). Of the 113 isolates obtained, 77% were hrHPV genotypes not included in the bivalent or quadrivalent vaccines, and 47% represented DNA types not covered in the nonavalent vaccine. Forty-seven percent of the women with hrHPV harbored a single genotype that was not covered by the nonavalent vaccine. CONCLUSION: A large fraction of hrHPV isolates from women participating in a cervical cancer screening program in northern Zimbabwe are DNA types not covered by the bivalent, quadrivalent, or nonavalent vaccines. These findings suggest the importance of characterizing the hrHPV DNA types isolated from cervical neoplasia in this population and determining whether cross-immunization against these genotypes develops after administration of the vaccines in current use. American Society of Clinical Oncology 2020-08-12 /pmc/articles/PMC7456322/ /pubmed/32783640 http://dx.doi.org/10.1200/GO.20.00286 Text en © 2020 by American Society of Clinical Oncology https://creativecommons.org/licenses/by-nc-nd/4.0/ Creative Commons Attribution Non-Commercial No Derivatives 4.0 License: https://creativecommons.org/licenses/by-nc-nd/4.0/
spellingShingle Original Reports
Thistle, Paul
Parpia, Rabea
Pain, Debanjan
Lee, Hang
Manasa, Justen
Schnipper, Lowell E.
Prevalence and Subtype Distribution of High-Risk Human Papillomavirus Among Women Presenting for Cervical Cancer Screening at Karanda Mission Hospital
title Prevalence and Subtype Distribution of High-Risk Human Papillomavirus Among Women Presenting for Cervical Cancer Screening at Karanda Mission Hospital
title_full Prevalence and Subtype Distribution of High-Risk Human Papillomavirus Among Women Presenting for Cervical Cancer Screening at Karanda Mission Hospital
title_fullStr Prevalence and Subtype Distribution of High-Risk Human Papillomavirus Among Women Presenting for Cervical Cancer Screening at Karanda Mission Hospital
title_full_unstemmed Prevalence and Subtype Distribution of High-Risk Human Papillomavirus Among Women Presenting for Cervical Cancer Screening at Karanda Mission Hospital
title_short Prevalence and Subtype Distribution of High-Risk Human Papillomavirus Among Women Presenting for Cervical Cancer Screening at Karanda Mission Hospital
title_sort prevalence and subtype distribution of high-risk human papillomavirus among women presenting for cervical cancer screening at karanda mission hospital
topic Original Reports
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7456322/
https://www.ncbi.nlm.nih.gov/pubmed/32783640
http://dx.doi.org/10.1200/GO.20.00286
work_keys_str_mv AT thistlepaul prevalenceandsubtypedistributionofhighriskhumanpapillomavirusamongwomenpresentingforcervicalcancerscreeningatkarandamissionhospital
AT parpiarabea prevalenceandsubtypedistributionofhighriskhumanpapillomavirusamongwomenpresentingforcervicalcancerscreeningatkarandamissionhospital
AT paindebanjan prevalenceandsubtypedistributionofhighriskhumanpapillomavirusamongwomenpresentingforcervicalcancerscreeningatkarandamissionhospital
AT leehang prevalenceandsubtypedistributionofhighriskhumanpapillomavirusamongwomenpresentingforcervicalcancerscreeningatkarandamissionhospital
AT manasajusten prevalenceandsubtypedistributionofhighriskhumanpapillomavirusamongwomenpresentingforcervicalcancerscreeningatkarandamissionhospital
AT schnipperlowelle prevalenceandsubtypedistributionofhighriskhumanpapillomavirusamongwomenpresentingforcervicalcancerscreeningatkarandamissionhospital